Teva calls halt to late-stage test of Rituxan biosimilar

Three years after Teva Pharmaceutical Industries ($TEVA) and Switzerland's Lonza joined forces to develop a few blockbuster biosimilars, one of their lead programs has hit an unexpected roadblock. The Israeli newspaper Haaretz reports that Teva has suspended its Phase III study of a biosimilar of Rituxan, one of the world's top-selling drugs from Roche ($RHHBY). Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.